Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;22(10):1629-32.
doi: 10.1007/s11695-012-0724-y.

Efficacy of laparoscopic greater curvature plication for weight loss and type 2 diabetes: 1-year follow-up

Affiliations

Efficacy of laparoscopic greater curvature plication for weight loss and type 2 diabetes: 1-year follow-up

Osama Taha. Obes Surg. 2012 Oct.

Abstract

Background: Laparoscopic greater curvature plication (LGCP) has gained popularity within the last 2 years because it is a restrictive procedure that reduces gastric volume without the need for stomach resection.

Methods: A prospective study was performed in which 55 morbidly obese patients with type 2 diabetes (44 female, 11 male) underwent LGCP. The patients had a mean age of 38.5 years (22-55 years), mean BMI of 43.5 kg/m(2) (35-52 kg/m(2)), and mean glycosylated hemoglobin (HbA1c) of 7.9 % (6-10 %).

Results: All procedures were completed laparoscopically. The mean operative time was 55 min (40-80 min), and the mean hospital stay was 1.8 days (1.5-5 days). No intraoperative or postoperative complications were reported apart from three cases of resistant nausea and vomiting and one case of intraluminal bleeding. The mean excess weight loss (EWL%) was 35 % (30-65 %) after 12 months with a mean BMI of 38 kg/m(2) after 12 months. A total of 23 % of patients stopped losing weight 6 months after the procedure, and 11 % began regaining about 14 % (12-20 %) of their EWL 9 months after the procedure. The mean HbA1c was 7.5 % (5.5-8 %) after 12 months.

Conclusions: LGCP is feasible and safe in the short term when applied to morbidly obese patients, but may be unsustainable. It is inferior as a restrictive procedure for resolution of type 2 diabetes. Longer follow-up and prospective comparative trials are needed to clarify whether it can be considered an effective single-stage procedure for treating morbidly obese diabetic patients and their comorbidities.

PubMed Disclaimer

References

    1. Ann Surg. 2008 Mar;247(3):401-7 - PubMed
    1. N Engl J Med. 2007 May 24;356(21):2176-83 - PubMed
    1. Diabetes Care. 2008 Feb;31 Suppl 2:S290-6 - PubMed
    1. J Laparoendosc Adv Surg Tech A. 2007 Dec;17(6):793-8 - PubMed
    1. ANZ J Surg. 2003 Aug;73(8):562 - PubMed

Publication types

MeSH terms

Substances